Results 231 to 240 of about 22,015 (248)

Biosimilars.

PDA journal of pharmaceutical science and technology, 2016
  +5 more sources

Biosimilarity

2018
openaire   +2 more sources

The advent of biosimilar therapies in rheumatology—“O Brave New World”

Nature Reviews Rheumatology, 2012
Jonathan Kay
exaly  

Rationale, Opportunities, and Reality of Biosimilar Medications

New England Journal of Medicine, 2018
Gary H Lyman, Robert Donald Harvey
exaly  

To switch or not to switch: that is the biosimilar question

Nature Reviews Gastroenterology and Hepatology, 2017
Silvio Danese, Laurent Peyrin-Biroulet
exaly  

Regulatory and clinical considerations for biosimilar oncology drugs

Lancet Oncology, The, 2014
Charles L Bennett, Brian K Chen, Michael D Wyatt   +2 more
exaly  

Bracing for the biosimilar wave

Nature Reviews Drug Discovery, 2017
exaly  

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

European Journal of Health Economics, 2014
Valentin Brodszky, Petra Baji, Márta Péntek   +2 more
exaly  

Can next-generation antibodies offset biosimilar competition?

Nature Reviews Drug Discovery, 2012
exaly  

Postmarket policy considerations for biosimilar oncology drugs

Lancet Oncology, The, 2016
Matthew J Renwick, Kate Smolina, Deirdre Weymann   +2 more
exaly